# 張杰教授 2025年論文摘要集
**北京大學口腔醫學院 口腔頜面外科**

用於翻譯練習（中英對照版）

---

## 1. Single-cell sequencing reveals tumor microenvironment features associated with the response to neoadjuvant immunochemotherapy in oral squamous cell carcinoma
**單細胞測序揭示口腔鱗狀細胞癌腫瘤微環境特徵與新輔助免疫化療反應的關係**

**PMID: 40105941 | Cancer Immunol Immunother | 2025 Mar**

### Abstract / 摘要

**Objectives:** In recent years, immune checkpoint inhibitors have shown promise as neoadjuvant therapies in the treatment of locally advanced oral squamous cell carcinoma (OSCC). However, the factors affecting the tumor response to immune checkpoint inhibitors (ICIs) remain unclear. This study aimed to analyze the impact of neoadjuvant chemoimmunotherapy (NACI) on the tumor microenvironment of OSCC via single-cell RNA sequencing, with the goal of optimizing treatment strategies.

**目的：** 近年來，免疫檢查點抑制劑作為新輔助治療在局部晚期口腔鱗狀細胞癌（OSCC）的治療中展現出良好前景。然而，影響腫瘤對免疫檢查點抑制劑（ICIs）反應的因素仍不清楚。本研究旨在通過單細胞RNA測序分析新輔助化療免疫治療（NACI）對OSCC腫瘤微環境的影響，以優化治療策略。

**Methods:** We analyzed biopsy, primary tumor, matched metastatic lymph node, and normal lymph node samples from four patients with OSCC receiving two cycles of tislelizumab (200 mg), albumin-bound paclitaxel (260 mg/m2), and cisplatin (60-75 mg/m2), with 3-week intervals between each cycle. This study explored the tumor microenvironment characteristics of tumors and metastatic lymph nodes in response to NACI.

**方法：** 我們分析了四名接受兩個週期替雷利珠單抗（200 mg）、白蛋白結合型紫杉醇（260 mg/m²）和順鉑（60-75 mg/m²）治療的OSCC患者的活檢標本、原發腫瘤、配對轉移淋巴結和正常淋巴結樣本，每個週期間隔3週。本研究探討了腫瘤和轉移淋巴結對NACI反應的腫瘤微環境特徵。

**Results:** We identified two major tumor cell subpopulations (C9 and C11), and patients with high expression of C11 subgroup-specific genes had a lower survival rate. FOXP3+ CD4 eTreg cells were found to potentially suppress the immune response. We found that NACI enhances antitumor immunity by promoting the proliferation of granzyme-expressing CD8+ T effector cells while simultaneously diminishing the effect of CD4+ T cells on Treg-mediated immune suppression. Furthermore, NACI was effective in suppressing inflammatory processes mediated by myeloid cells in tumors, contributing to its antitumor effects. The CCL19+ fibroblastic reticular cell (FRC) subgroup was significantly associated with the efficacy of NACI in patients with OSCC. We found that CCL19+ FRCs primarily exert their antitumor effects through interactions with CD8+ T lymphocytes via the CXCL12‒CXCR4 axis.

**結果：** 我們鑑定出兩個主要的腫瘤細胞亞群（C9和C11），高表達C11亞群特異性基因的患者生存率較低。發現FOXP3+ CD4 eTreg細胞可能抑制免疫反應。我們發現NACI通過促進表達顆粒酶的CD8+ T效應細胞增殖來增強抗腫瘤免疫，同時減弱CD4+ T細胞對Treg介導的免疫抑制作用。此外，NACI有效抑制腫瘤中髓系細胞介導的炎症過程，有助於其抗腫瘤作用。CCL19+纖維網狀細胞（FRC）亞群與OSCC患者NACI療效顯著相關。我們發現CCL19+ FRC主要通過CXCL12-CXCR4軸與CD8+ T淋巴細胞相互作用發揮抗腫瘤作用。

**Conclusion:** We explored the immune landscape of primary OSCC tumors and metastatic lymph nodes in relation to clinical response to NACI. Our findings offer valuable insights into patient treatment responses and highlight potential new therapeutic targets for the future management of OSCC.

**結論：** 我們探討了原發性OSCC腫瘤和轉移淋巴結的免疫圖譜與NACI臨床反應的關係。我們的發現為患者治療反應提供了寶貴的見解，並為OSCC的未來治療指出了潛在的新治療靶點。

**Keywords:** CCL19+ fibroblastic reticular cell; Neoadjuvant chemoimmunotherapy; Oral squamous cell carcinoma; Tumor microenvironment.

**關鍵詞：** CCL19+纖維網狀細胞；新輔助化療免疫治療；口腔鱗狀細胞癌；腫瘤微環境

---

## 2. Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis
**新輔助化療免疫治療為局部晚期口腔或口咽癌患者帶來更優質的生活質量：傾向評分匹配分析**

**PMID: 40015212 | Oral Oncol | 2025 Mar**

### Abstract / 摘要

**Background:** The outcomes and quality of life of patients with locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC) following upfront surgery (US) are suboptimal. The optimal neoadjuvant therapy involving programmed death-1 inhibitors still remains unknown. We aimed to investigate the antitumor efficacy and quality-of-life benefits of neoadjuvant chemoimmunotherapy (NACI) and compare them with those of US for LAOOPSCC.

**背景：** 局部晚期口腔或口咽鱗狀細胞癌（LAOOPSCC）患者接受直接手術（US）後的療效和生活質量並不理想。涉及程序性死亡受體-1抑制劑的最佳新輔助治療方案仍不明確。我們旨在研究新輔助化療免疫治療（NACI）的抗腫瘤療效和生活質量獲益，並與LAOOPSCC直接手術進行比較。

**Methods:** A total of 570 patients with OOPSCC who underwent surgical treatment between January 2021 and January 2023 were initially reviewed and we obtained 51 unbiased patients in each of the NACI and US groups through propensity score matching based on age, sex, clinical T and N stage. The antitumor efficacy in patients in the NACI group was evaluated with the pathological response. The postoperative quality of life, as assessed with the EORTC Quality of Life Questionnaire Head and Neck 35, as well as disease-free survival and overall survival, were compared between the groups.

**方法：** 我們初步回顧了2021年1月至2023年1月期間接受手術治療的570例OOPSCC患者，並通過基於年齡、性別、臨床T和N分期的傾向評分匹配，在NACI組和US組各獲得51例無偏倚患者。NACI組患者的抗腫瘤療效通過病理反應進行評估。採用EORTC生活質量問卷頭頸35評估術後生活質量，並比較兩組的無病生存期和總生存期。

**Results:** In the NACI group, the major pathological response rate was 58.8% (30/51), and the objective response rate was 66.7% (34/51). In the NACI group, patients experienced a shorter operative time (p = 0.001) and a reduced length of hospitalization post-surgery (p = 0.041), along with less intraoperative blood loss (p < 0.001) and fewer free flap reconstructions (p < 0.001). Compared with the patients in the US group, those in the NACI group had significantly better postoperative quality of life, including the sensory function (12.7 vs. 23.0, p = 0.021), speech problems (17.3 vs. 35.1, p < 0.001), social eating (20.8 vs. 31.0, p = 0.020), social contact (19.8 vs. 36.5, p < 0.001) and feeling ill (41.2 vs. 51.6, p = 0.021). There was no significant statistical difference in OS (p = 0.825) and DFS (p = 0.473) between the two groups.

**結果：** NACI組的主要病理反應率為58.8%（30/51），客觀緩解率為66.7%（34/51）。NACI組患者手術時間更短（p = 0.001），術後住院時間更短（p = 0.041），術中出血量更少（p < 0.001），游離皮瓣重建更少（p < 0.001）。與US組患者相比，NACI組患者術後生活質量明顯更好，包括感覺功能（12.7 vs. 23.0，p = 0.021）、言語問題（17.3 vs. 35.1，p < 0.001）、社交進食（20.8 vs. 31.0，p = 0.020）、社交接觸（19.8 vs. 36.5，p < 0.001）和疾病感受（41.2 vs. 51.6，p = 0.021）。兩組的OS（p = 0.825）和DFS（p = 0.473）無顯著統計學差異。

**Conclusion:** The findings demonstrate the safety and feasibility of NACI and the de-escalation surgery after NACI is worth promoting to improve patient postoperative quality of life.

**結論：** 研究結果表明NACI安全可行，NACI後的降階梯手術值得推廣以改善患者術後生活質量。

**Keywords:** Chemoimmunotherapy; Head and neck squamous cell carcinoma; Neoadjuvant; Propensity score analysis.

**關鍵詞：** 化療免疫治療；頭頸部鱗狀細胞癌；新輔助治療；傾向評分分析

---

## 3. Patterns of lymph node metastasis and treatment outcomes of parotid gland malignancies
**腮腺惡性腫瘤的淋巴結轉移模式及治療結果**

**PMID: 39987446 | BMC Oral Health | 2025 Feb**

### Abstract / 摘要

**Background:** This study aimed to characterize the pattern of cervical lymph node spread and evaluate prognostic factors and outcomes of surgery and postoperative adjuvant therapy in primary parotid carcinoma (PPC).

**背景：** 本研究旨在描述頸淋巴結擴散模式，並評估原發性腮腺癌（PPC）手術和術後輔助治療的預後因素和結果。

**Methods:** We retrospectively enrolled 136 patients with PPC. The primary outcomes were disease-free survival (DFS) and overall survival (OS). We used Cox hazards models to assess variables influencing survival, and chi-square tests and logistic regression models to evaluate correlations between pN+ and clinicopathological factors.

**方法：** 我們回顧性納入136例PPC患者。主要結局為無病生存期（DFS）和總生存期（OS）。我們使用Cox風險模型評估影響生存的變量，使用卡方檢驗和邏輯回歸模型評估pN+與臨床病理因素之間的相關性。

**Results:** Pathology-confirmed lymph node metastasis was detected in 60.0% and 84.1% of the patients with cT1-2 and cT3-4 tumors, respectively. The occult metastasis rate in cN0 was 55.2%. Level II metastasis was most common (93.2%), followed by level I (49.3%). Histological type, histologic grade, pT stage, and AJCC stage were significant risk factors for lymph node metastasis. One- and five-year OS were 86.0% and 49.3%, respectively (median, 60 months) and 71.6% and 34.8%, respectively, for DFS (median, 24 months). Surgery with 125I seed implant brachytherapy conferred survival benefits to patients. Predictive factors for DFS were pT stage, pN stage, histological type, histological grade, and management strategy, and for OS, pT stage, pN stage, histological type, and histological grade.

**結果：** 病理證實的淋巴結轉移在cT1-2和cT3-4腫瘤患者中分別為60.0%和84.1%。cN0的隱匿性轉移率為55.2%。II區轉移最常見（93.2%），其次是I區（49.3%）。組織學類型、組織學分級、pT分期和AJCC分期是淋巴結轉移的重要危險因素。1年和5年OS分別為86.0%和49.3%（中位數60個月），DFS分別為71.6%和34.8%（中位數24個月）。125I粒子植入近距離放療聯合手術為患者帶來生存獲益。DFS的預測因素為pT分期、pN分期、組織學類型、組織學分級和治療策略；OS的預測因素為pT分期、pN分期、組織學類型和組織學分級。

**Conclusion:** Histological high grade and advanced T classification were associated with occult lymph node metastasis. Postoperative radiotherapy (RT)/radiochemotherapy (RCT), conferred significant survival benefits in PPC. Neck dissection in patients with cN0 cancer significantly improved DFS and should be performed on those with high-grade and/or advanced T-stage tumors.

**結論：** 高組織學分級和晚期T分期與隱匿性淋巴結轉移相關。術後放療（RT）/放化療（RCT）為PPC患者帶來顯著的生存獲益。cN0癌症患者的頸淋巴結清掃術顯著改善DFS，應對高分級和/或晚期T分期腫瘤患者實施。

**Keywords:** Cervical lymph node metastasis; Neck dissection; Occult metastasis; Primary parotid carcinoma; Survival.

**關鍵詞：** 頸淋巴結轉移；頸淋巴結清掃術；隱匿性轉移；原發性腮腺癌；生存

---

## 4. Integrated peripheral blood multi-omics profiling identifies immune signatures predictive of neoadjuvant PD-1 blockade efficacy in head and neck squamous cell carcinoma
**外周血多組學整合分析鑑定預測頭頸部鱗狀細胞癌新輔助PD-1阻斷療效的免疫特徵**

**PMID: 40544277 | J Transl Med | 2025 Jun**

### Abstract / 摘要

**Background:** Neoadjuvant PD-1 inhibitor therapy has shown promise in locally advanced head and neck squamous cell carcinoma (HNSCC), but only a subset of patients achieves major pathological responses. Liquid biopsy, the analysis of tumor-derived biomarkers in readily accessible bodily fluids (primarily blood), offers significant advantages over traditional tissue biopsies for predicting cancer treatment outcomes. The aim of this study is to develop a predictive model for neoadjuvant PD-1 therapy response in HNSCC patients using exclusively liquid biopsy approaches—namely, peripheral blood immune profiling (CyTOF) and plasma cytokine panels (Olink).

**背景：** 新輔助PD-1抑制劑治療在局部晚期頭頸部鱗狀細胞癌（HNSCC）中展現出良好前景，但僅部分患者能獲得主要病理反應。液體活檢，即分析易於獲取的體液（主要是血液）中腫瘤來源的生物標誌物，在預測癌症治療結果方面比傳統組織活檢具有顯著優勢。本研究旨在僅使用液體活檢方法——即外周血免疫分析（CyTOF）和血漿細胞因子面板（Olink）——為HNSCC患者開發新輔助PD-1治療反應的預測模型。

**Methods:** In a prospective trial involving 50 HNSCC patients treated with neoadjuvant tislelizumab plus chemotherapy, peripheral blood samples were collected pre- and post-treatment. Immune cell subsets were analyzed by mass cytometry (CyTOF), and circulating protein markers were quantified via a 92-plex targeted proteomics panel (Olink). Multimodal features were integrated into a predictive model using logistic regression.

**方法：** 在一項納入50例接受新輔助替雷利珠單抗聯合化療的HNSCC患者的前瞻性試驗中，收集治療前後的外周血樣本。通過質譜流式細胞術（CyTOF）分析免疫細胞亞群，通過92重靶向蛋白質組學面板（Olink）定量循環蛋白標誌物。使用邏輯回歸將多模態特徵整合到預測模型中。

**Results:** Baseline immune profiles differed significantly between responder (RD) and non-responder (NRD): RD showed higher frequencies of CD103-CD8+ central memory T cells (Tcm, c03) and elevated plasma interleukins (IL-5, IL-13), whereas NRD had more CD28-TIGIThighcPARP-CD8+ terminally differentiated effector memory CD45RA+ T cells (Temra, c17) and higher levels of chemokines (CCL3, CCL4) and MMP7. Neoadjuvant therapy reactivated both subsets, evidenced by downregulation of PD-1 and increased expression of activation markers (e.g., CD38) and cytotoxic mediators (e.g., granzyme B and interferon γ). A multimodal predictive model incorporating CD8+T cell subsets (c03, c17) and plasma biomarkers (IL-5, MMP7) demonstrated superior predictive accuracy (AUC = 0.9219).

**結果：** 反應者（RD）和非反應者（NRD）的基線免疫譜存在顯著差異：RD顯示更高頻率的CD103-CD8+中央記憶T細胞（Tcm，c03）和升高的血漿白介素（IL-5、IL-13），而NRD有更多CD28-TIGIThighcPARP-CD8+終末分化效應記憶CD45RA+ T細胞（Temra，c17）和更高水平的趨化因子（CCL3、CCL4）及MMP7。新輔助治療重新激活了兩個亞群，表現為PD-1下調和活化標誌物（如CD38）及細胞毒性介質（如顆粒酶B和干擾素γ）表達增加。整合CD8+ T細胞亞群（c03、c17）和血漿生物標誌物（IL-5、MMP7）的多模態預測模型顯示出優越的預測準確性（AUC = 0.9219）。

**Conclusions:** Integrated peripheral immune profiling enables robust, noninvasive prediction of neoadjuvant PD-1 blockade efficacy in HNSCC. The identified immune cell subsets and plasma biomarkers provide a clinically applicable framework for early response stratification and personalized immunotherapy, supporting liquid biopsy as a viable platform for clinical decision-making.

**結論：** 外周免疫譜整合分析能夠穩健、無創地預測HNSCC新輔助PD-1阻斷療效。鑑定的免疫細胞亞群和血漿生物標誌物為早期反應分層和個體化免疫治療提供了臨床適用的框架，支持液體活檢作為臨床決策的可行平台。

**Keywords:** Head and neck squamous cell carcinoma; Liquid biopsy; Multi-omics research; Neoadjuvant therapy; PD-1 inhibitor.

**關鍵詞：** 頭頸部鱗狀細胞癌；液體活檢；多組學研究；新輔助治療；PD-1抑制劑

---

## 5. Correlation between maxillary defect and facial asymmetry
**上頜骨缺損與面部不對稱的相關性**

**PMID: 39870547 | Int J Oral Maxillofac Surg | 2025 Jul**

### Abstract / 摘要

The aim of this study was to evaluate the correlation between maxillary defects and facial asymmetry, and to establish categories for visual perception of facial asymmetry. The facial data of 47 patients who underwent maxillary resection due to tumors were captured using stereophotogrammetry. Facial asymmetry was measured using a landmark-independent method and assessed with a Likert scale. Facial asymmetry was classified into three grades (I-III) based on visual perception. Statistically significant differences (P < 0.001) were found in the asymmetry of the suborbital, zygomatic, buccal, and superolabial areas among the different visual perception categories, and the symmetry of these areas significantly influenced the visual perception (P < 0.001). The maxillary defect magnitude significantly influenced facial asymmetry perception (P < 0.001). Substantial statistical variations (P < 0.001) in the asymmetry of four facial areas, excluding the masseteric and nasal areas, across the different classes of maxillary defect were noted. Maxillary defects significantly affect the midface soft tissue symmetry. Reconstruction should focus on sufficient soft tissue support in the zygomatic, buccal, suborbital, and superolabial areas. Corrective measures are generally unnecessary for grade I asymmetry. For grade II asymmetry, reconstruction can be decided individually. For grade III asymmetry, reconstruction is essential.

本研究旨在評估上頜骨缺損與面部不對稱的相關性，並建立面部不對稱視覺感知的分類標準。採用立體攝影測量法採集47例因腫瘤行上頜骨切除術患者的面部數據。使用非標誌點依賴方法測量面部不對稱，並採用李克特量表進行評估。根據視覺感知將面部不對稱分為三級（I-III）。在不同視覺感知類別中，眶下區、顴部、頰部和上唇上區的不對稱存在統計學顯著差異（P < 0.001），這些區域的對稱性顯著影響視覺感知（P < 0.001）。上頜骨缺損程度顯著影響面部不對稱感知（P < 0.001）。在不同類型的上頜骨缺損中，除咬肌區和鼻區外，四個面部區域的不對稱存在顯著統計學差異（P < 0.001）。上頜骨缺損顯著影響中面部軟組織對稱性。重建應注重顴部、頰部、眶下區和上唇上區的充分軟組織支撐。I級不對稱通常無需矯正措施。II級不對稱可個體化決定是否重建。III級不對稱則必須進行重建。

**Keywords:** Facial asymmetry; Maxilla; Photogrammetry; Three-dimensional imaging; Visual perception.

**關鍵詞：** 面部不對稱；上頜骨；攝影測量法；三維成像；視覺感知

---

## 6. Reconstructing defects following radical parotidectomy using superficial circumflex Iliac perforator flaps
**使用旋髂淺動脈穿支皮瓣修復腮腺根治術後缺損**

**PMID: 40050935 | BMC Oral Health | 2025 Mar**

### Abstract / 摘要

**Background:** The restoration of tissue defects following radical parotidectomy poses significant challenges due to the complex anatomy and functional requirements of the region. The superficial circumflex iliac perforator (SCIP) flap presents several advantages, including its adjustable volume, the potential for chimerism with bone, and the ability to conceal scarring. This study was conducted to assess the effectiveness and safety of SCIP flaps in reconstructing defects after radical parotidectomy.

**背景：** 腮腺根治術後組織缺損的修復因該區域複雜的解剖結構和功能要求而面臨重大挑戰。旋髂淺動脈穿支皮瓣（SCIP）具有多項優勢，包括可調節的體積、與骨組織嵌合的潛力以及隱藏瘢痕的能力。本研究旨在評估SCIP皮瓣修復腮腺根治術後缺損的有效性和安全性。

**Methods:** This retrospective study included patients who underwent reconstruction of defects after radical parotidectomy using SCIP flaps between June 2023 and June 2024. Facial nerve reanimation was achieved through the use of cervical sensory nerve grafts. Detailed records were maintained on patient demographics, flap dimensions, pedicle length, duration of surgery, complications at the donor or recipient sites, and the survival status of the flaps.

**方法：** 這項回顧性研究納入了2023年6月至2024年6月期間使用SCIP皮瓣修復腮腺根治術後缺損的患者。通過頸部感覺神經移植實現面神經功能重建。詳細記錄患者人口統計學資料、皮瓣尺寸、蒂部長度、手術時間、供區或受區併發症以及皮瓣存活狀態。

**Results:** The study included 10 patients (4 males, 6 females) with a median age of 45.5 years. Four had T3 tumors and six had T4 tumors. Facial nerve reanimation was performed in 9 patients. Flap sizes ranged from 4 cm×8 cm to 6 cm×10 cm, and pedicle lengths from 4 cm to 9 cm. Duration of operation ranged from 210 to 450 min. Six patients underwent postoperative radiotherapy. All flaps survived without radiation-related recipient complications or donor site complications.

**結果：** 研究納入10例患者（4男6女），中位年齡45.5歲。4例為T3腫瘤，6例為T4腫瘤。9例患者進行了面神經功能重建。皮瓣尺寸範圍為4 cm×8 cm至6 cm×10 cm，蒂部長度為4 cm至9 cm。手術時間為210至450分鐘。6例患者接受了術後放療。所有皮瓣均存活，無放療相關受區併發症或供區併發症。

**Conclusion:** The use of SCIP flaps has been demonstrated to be a viable and safe option for the reconstruction of defects resulting from radical parotidectomy when combined with nerve grafting techniques.

**結論：** SCIP皮瓣聯合神經移植技術已被證明是修復腮腺根治術後缺損的可行且安全的選擇。

**Keywords:** Iliac artery; Microsurgical free flaps; Parotid neoplasms; Perforator flap; Rehabilitation.

**關鍵詞：** 髂動脈；顯微外科游離皮瓣；腮腺腫瘤；穿支皮瓣；康復

---

## 7. Use of Superficial Temporal Vessels in Reconstructive Oral and Maxillofacial Surgery With Vascularized Free Flaps Among "Frozen Neck" Patients
**顳淺血管在"冰凍頸"患者口腔頜面外科血管化游離皮瓣重建中的應用**

**PMID: 41255777 | Laryngoscope Investig Otolaryngol | 2025 Nov**

### Abstract / 摘要

**Background:** This study aimed to evaluate the feasibility of using superficial temporal vessels as recipient vessels for vascularized free flap reconstruction in "frozen neck" patients following radiotherapy for head and neck cancer (HNC).

**背景：** 本研究旨在評估顳淺血管作為受區血管在頭頸癌（HNC）放療後"冰凍頸"患者血管化游離皮瓣重建中的可行性。

**Methods:** Between February 2022 and November 2024, 16 patients underwent vascularized free flap reconstruction by using superficial temporal vessels at Peking University School and Hospital of Stomatology. Among them, anterolateral thigh flap (ALT, n = 5), radial forearm free flap (RFFF, n = 1), deep circumflex iliac artery microvascular free flap (DCIA, n = 8), and superficial iliac circumflex artery perforator flap (SCIP, n = 2) were utilized. Intraoperative vessel identification, flap survival, and postoperative complications were assessed.

**方法：** 2022年2月至2024年11月期間，16例患者在北京大學口腔醫學院接受了使用顳淺血管的血管化游離皮瓣重建。其中使用股前外側皮瓣（ALT，n = 5）、橈側前臂游離皮瓣（RFFF，n = 1）、旋髂深動脈顯微血管游離皮瓣（DCIA，n = 8）和旋髂淺動脈穿支皮瓣（SCIP，n = 2）。評估術中血管識別、皮瓣存活和術後併發症。

**Results:** All patients attained optimal surgical outcomes. During the mean follow-up period of 9 months, all flaps survived with absence of major procedure-related morbidity.

**結果：** 所有患者均獲得理想的手術結果。在平均9個月的隨訪期間，所有皮瓣均存活，無重大手術相關併發症。

**Conclusion:** Superficial temporal vessels offer a safe, reliable approach for vascularized free flap reconstruction in challenging "frozen neck" cases, providing an effective alternative in oral-maxillofacial reconstruction.

**結論：** 顳淺血管為具有挑戰性的"冰凍頸"病例提供了安全、可靠的血管化游離皮瓣重建方法，是口腔頜面部重建的有效替代方案。

**Keywords:** anastomosis; frozen neck; head and neck cancer; radiotherapy; superficial temporal vessels.

**關鍵詞：** 吻合術；冰凍頸；頭頸癌；放療；顳淺血管

---

## 8. Reconstruction of lower lip defects with chimeric nasolabial flap with buccal artery myomucosal flap
**嵌合鼻唇溝皮瓣聯合頰動脈肌黏膜瓣修復下唇缺損**

**PMID: 39855302 | J Stomatol Oral Maxillofac Surg | 2025 Jun**

### Abstract / 摘要

**Purpose:** This study aimed to evaluate a chimeric flap comprising a nasolabial flap and a buccal artery myomucosal flap used to reconstruct a large defect of the lower lip.

**目的：** 本研究旨在評估由鼻唇溝皮瓣和頰動脈肌黏膜瓣組成的嵌合皮瓣修復下唇大面積缺損的效果。

**Materials and methods:** From November 2019 to August 2022, seven patients with lower lip carcinoma underwent radical resection and reconstruction. A chimeric flap comprising a nasolabial flap and a buccal artery myomucosal flap was used to reconstruct the large defect of the lower lip. Postoperative observations included flap healing, mouth opening, and lip competence.

**材料與方法：** 2019年11月至2022年8月，7例下唇癌患者接受了根治性切除和重建。採用由鼻唇溝皮瓣和頰動脈肌黏膜瓣組成的嵌合皮瓣修復下唇大面積缺損。術後觀察指標包括皮瓣癒合、張口度和唇功能。

**Results:** Seven patients with lower lip carcinomas underwent radical resection and reconstruction. The flap survived without complications in 6 patients; 1 patient showed marginal necrosis of the skin paddle. The reconstructed lower lip had an adequate lip length and height, and its appearance was acceptable. The mouth opening ranged from 2.5 cm to 3.5 cm. All patients were able to intake oral diet in a public setting.

**結果：** 7例下唇癌患者接受了根治性切除和重建。6例患者皮瓣存活無併發症；1例患者出現皮島邊緣壞死。重建的下唇具有足夠的唇長度和高度，外觀可接受。張口度為2.5 cm至3.5 cm。所有患者均能在公共場合進行口服飲食。

**Conclusions:** The chimeric flap, comprising a nasolabial flap and a buccal artery myomucosal flap, offers a method for reconstructing near-total and total defects of the lower lip.

**結論：** 由鼻唇溝皮瓣和頰動脈肌黏膜瓣組成的嵌合皮瓣為修復下唇近全部和全部缺損提供了一種方法。

**Keywords:** Buccal artery myomucosal flap; Chimeric flap; Lower lip defect; Nasolabial flap; Reconstruction.

**關鍵詞：** 頰動脈肌黏膜瓣；嵌合皮瓣；下唇缺損；鼻唇溝皮瓣；重建

---

## 9. Role of 18F-FDG PET/CT radiomics in predicting lymph node metastasis and prognosis in oral squamous cell carcinoma
**18F-FDG PET/CT影像組學在預測口腔鱗狀細胞癌淋巴結轉移和預後中的作用**

**PMID: 41478255 | Radiography (Lond) | 2025 Dec**

### Abstract / 摘要

**Introduction:** This study aimed to develop and validate 18F-FDG positron emission tomography/computed tomography (PET/CT) radiomics-based models for predicting cervical lymph node metastasis (LNM) and prognosis (overall survival [OS] and disease-free survival [DFS]) in patients with oral squamous cell carcinoma (OSCC).

**引言：** 本研究旨在開發和驗證基於18F-FDG正電子發射斷層掃描/計算機斷層掃描（PET/CT）影像組學的模型，用於預測口腔鱗狀細胞癌（OSCC）患者的頸淋巴結轉移（LNM）和預後（總生存期[OS]和無病生存期[DFS]）。

**Methods:** We retrospectively enrolled 130 patients with OSCC who underwent surgery. A total of 107 radiomics features were extracted from the primary tumor. Least absolute shrinkage and selection operator (LASSO) regression and random forest algorithms were applied for feature selection. Multivariable logistic regression (for LNM) and Cox regression (for OS/DFS) models integrating selected radiomics and clinical features were constructed. Model performance was evaluated using receiver operating characteristic (ROC) curves, concordance index (C-index), calibration curves, and decision curve.

**方法：** 我們回顧性納入130例接受手術的OSCC患者。從原發腫瘤中提取107個影像組學特徵。應用最小絕對收縮和選擇算子（LASSO）回歸和隨機森林算法進行特徵選擇。構建整合所選影像組學和臨床特徵的多變量邏輯回歸（用於LNM）和Cox回歸（用於OS/DFS）模型。使用受試者工作特徵（ROC）曲線、一致性指數（C-index）、校準曲線和決策曲線評估模型性能。

**Results:** The LNM diagnostic model, which incorporated three radiomics features (GLCM_Correlation, GLCM_Imc1, and GLCM_JointEnergy) and two clinical features (cT and cN), achieved an area under the curve (AUC) of 0.856 and an accuracy of 81.5%, outperforming conventional visual PET/CT assessment (accuracy = 74.6%). For prognosis, the combined radiomic-clinical models for OS and DFS yielded C-indexes of 0.716 and 0.683, respectively, both significantly higher than those of TNM stage (0.630 and 0.594). Both prognostic models successfully stratified patients into high- and low-risk groups with significant survival differences (p < 0.01).

**結果：** LNM診斷模型納入了三個影像組學特徵（GLCM_Correlation、GLCM_Imc1和GLCM_JointEnergy）和兩個臨床特徵（cT和cN），曲線下面積（AUC）達到0.856，準確率為81.5%，優於傳統視覺PET/CT評估（準確率 = 74.6%）。在預後方面，OS和DFS的聯合影像組學-臨床模型的C-index分別為0.716和0.683，均顯著高於TNM分期（0.630和0.594）。兩個預後模型均成功將患者分為高風險和低風險組，生存差異顯著（p < 0.01）。

**Conclusion:** PET/CT radiomics significantly improved the diagnostic accuracy for cervical LNM and possessed the potential as a supplementary component for the TNM staging system.

**結論：** PET/CT影像組學顯著提高了頸部LNM的診斷準確性，具有作為TNM分期系統補充成分的潛力。

**Keywords:** Lymph node metastasis; Oral squamous cell carcinoma; Positron emission tomography/computed tomography; Prognosis; Radiomics.

**關鍵詞：** 淋巴結轉移；口腔鱗狀細胞癌；正電子發射斷層掃描/計算機斷層掃描；預後；影像組學

---

## 10. Deep learning-based auto-segmentation model for clinical target volume delineation in brachytherapy after parotid cancer surgery
**基於深度學習的自動分割模型用於腮腺癌術後近距離放療臨床靶區勾畫**

**PMID: 41048621 | J Contemp Brachytherapy | 2025 Aug**

### Abstract / 摘要

**Purpose:** Timely and accurate delineation of the clinical target volume (CTV) in brachytherapy after parotid cancer surgery plays a crucial role in tailored delivery of radiation doses. This study aimed to develop and evaluate a deep learning-based model for auto-segmentation of the CTVs in postoperative adjuvant brachytherapy for patients with parotid gland cancer, addressing the challenge of achieving consistent, high-quality CTV delineations efficiently.

**目的：** 腮腺癌術後近距離放療中臨床靶區（CTV）的及時準確勾畫對於個體化放射劑量遞送至關重要。本研究旨在開發和評估基於深度學習的模型，用於腮腺癌患者術後輔助近距離放療CTV的自動分割，以解決高效實現一致、高質量CTV勾畫的挑戰。

**Material and methods:** Using clinical imaging data from 326 patients with parotid gland carcinoma treated at Peking University School and Hospital of Stomatology between 2017 and 2023, we established a training dataset of 213 cases, a validation set of 53 cases, and a test set of 60 cases. The CTVs on the images were segmented using 3D Res-UNet, a deep learning model, and compared against manual delineations performed by experienced radiation oncologists. The performance of 3D Res-UNet was optimized through a comprehensive preprocessing and training process tailored to the dataset's characteristics.

**材料與方法：** 使用2017年至2023年在北京大學口腔醫學院接受治療的326例腮腺癌患者的臨床影像數據，我們建立了213例的訓練數據集、53例的驗證集和60例的測試集。使用深度學習模型3D Res-UNet對圖像上的CTV進行分割，並與經驗豐富的放療腫瘤科醫生的手動勾畫進行比較。通過針對數據集特徵的綜合預處理和訓練過程優化3D Res-UNet的性能。

**Results:** The deep learning model yielded a significant improvement in segmentation efficiency. The deep learning model generated initial CTV contours in 9.4 seconds of computational time. Subsequent expert review and minor adjustments required an average of 11.9 minutes, substantially shorter than the 46.7 minutes needed for fully manual delineation. Quantitative analysis showed that the Dice similarity coefficient (DSC) of automatic segmentation by 3D Res-UNet was 0.709, which improved to 0.924 after expert review. Qualitative evaluation by senior oncologists further affirmed the clinical acceptability of the automatically segmented CTVs.

**結果：** 深度學習模型顯著提高了分割效率。深度學習模型在9.4秒的計算時間內生成初始CTV輪廓。隨後的專家審核和微調平均需要11.9分鐘，明顯短於完全手動勾畫所需的46.7分鐘。定量分析顯示，3D Res-UNet自動分割的Dice相似係數（DSC）為0.709，經專家審核後提高至0.924。資深腫瘤科醫生的定性評估進一步肯定了自動分割CTV的臨床可接受性。

**Conclusions:** Automatic contouring with physician review enabled high-accuracy and rapid CTV generation, reducing the overall delineation workload by more than 30 minutes. Consequently, the proposed deep-learning model functions as a useful support tool that streamlines postoperative adjuvant brachytherapy planning for parotid gland cancer and lessens the burden on radiation oncologists, thereby contributing to improved patient care.

**結論：** 自動勾畫結合醫生審核實現了高準確性和快速CTV生成，將整體勾畫工作量減少了30多分鐘。因此，所提出的深度學習模型作為有用的輔助工具，簡化了腮腺癌術後輔助近距離放療計劃，減輕了放療腫瘤科醫生的負擔，從而有助於改善患者護理。

**Keywords:** auto-segmentation; brachytherapy; clinical target volume; parotid gland cancer.

**關鍵詞：** 自動分割；近距離放療；臨床靶區；腮腺癌

---

## 11. Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: A single-arm phase II clinical trial
**新輔助替雷利珠單抗聯合化療治療局部晚期口腔和口咽鱗狀細胞癌：單臂II期臨床試驗**

**PMID: 41352160 | Oral Oncol | 2026 Jan**

### Abstract / 摘要

**Background:** This study aimed to evaluate the antitumor effect and safety of neoadjuvant chemotherapy plus tislelizumab (a programmed death-1 inhibitor) for the treatment of resectable locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC).

**背景：** 本研究旨在評估新輔助化療聯合替雷利珠單抗（一種程序性死亡受體-1抑制劑）治療可切除的局部晚期口腔或口咽鱗狀細胞癌（LAOOPSCC）的抗腫瘤效果和安全性。

**Methods:** Eligible patients with stage III-IV LAOOPSCC were treated with two cycles of tislelizumab (200 mg), albumin-bound paclitaxel (260 mg/m2), and cisplatin (60-75 mg/m2) with a three-week interval between each cycle; this treatment was followed by surgery and adjuvant radiotherapy or concurrent chemoradiotherapy. The primary endpoints were the major pathological response (MPR) rate and safety.

**方法：** 符合條件的III-IV期LAOOPSCC患者接受兩個週期的替雷利珠單抗（200 mg）、白蛋白結合型紫杉醇（260 mg/m²）和順鉑（60-75 mg/m²）治療，每個週期間隔3週；之後進行手術和輔助放療或同步放化療。主要終點為主要病理反應（MPR）率和安全性。

**Results:** Between March 2022 and June 2023, a total of 82 patients were eligible and completed two cycles of neoadjuvant therapy; 78 patients underwent imaging evaluation, and 73 underwent surgery and pathological response evaluation. Forty patients underwent de-escalation surgery for the primary tumor. Orbital floor resection was avoided in 1 patient, mandibulectomy was avoided in 5 patients, and near-total glossectomy or total glossectomy was avoided in 32 patients. An objective response rate of 67.9% and an MPR rate of 60.3% were achieved, with 34.2% of patients achieving a pathological complete response. With a median follow-up time of 24 months, the two-year overall survival rate was 84.4%, and the two-year event-free survival rate was 76.7%. Treatment-related adverse events of grade 3 or 4 occurred in 11 patients (13.4%) during the neoadjuvant therapy.

**結果：** 2022年3月至2023年6月期間，共82例患者符合條件並完成了兩個週期的新輔助治療；78例患者接受了影像學評估，73例接受了手術和病理反應評估。40例患者對原發腫瘤進行了降階梯手術。1例患者避免了眶底切除，5例患者避免了下頜骨切除，32例患者避免了近全舌切除或全舌切除。客觀緩解率為67.9%，MPR率為60.3%，34.2%的患者達到病理完全緩解。中位隨訪時間為24個月，2年總生存率為84.4%，2年無事件生存率為76.7%。新輔助治療期間，11例患者（13.4%）發生3級或4級治療相關不良事件。

**Conclusions:** Neoadjuvant tislelizumab plus chemotherapy for LAOOPSCC achieved a high pathological response rate and favorable survival metrics with an acceptable safety profile.

**結論：** 新輔助替雷利珠單抗聯合化療治療LAOOPSCC獲得了較高的病理反應率和良好的生存指標，安全性可接受。

**Keywords:** Chemotherapy; Head and neck; Immunotherapy; Neoadjuvant; Squamous cell carcinoma.

**關鍵詞：** 化療；頭頸部；免疫治療；新輔助治療；鱗狀細胞癌

---

## 12. Is the use of intraoperative vasopressors associated with flap failure in head and neck free tissue transfer surgery?
**頭頸部游離組織移植手術中術中血管收縮劑的使用是否與皮瓣失敗相關？**

**PMID: 40914291 | J Stomatol Oral Maxillofac Surg | 2025 Sep**

### Abstract / 摘要

**Background:** Maintaining appropriate blood pressure during head and neck free tissue transfer surgery is important for both organ and flap perfusion. However, the use of vasopressors to treat intraoperative hypotension is controversial. The purpose of this prospective cohort study is to evaluate the impact of intraoperative vasopressors on the incidence of flap necrosis.

**背景：** 頭頸部游離組織移植手術中維持適當的血壓對器官和皮瓣灌注都很重要。然而，使用血管收縮劑治療術中低血壓存在爭議。本前瞻性隊列研究旨在評估術中血管收縮劑對皮瓣壞死發生率的影響。

**Methods:** This prospective cohort study examined patients undergoing free tissue transfer surgery of the head and neck between January 2020 and December 2021 at Peking University School and Hospital of Stomatology. Exclusion criteria included history of preoperative radiotherapy or smoking and American Society of Anesthesiologists (ASA) physical status classification IV or V. The predictor variable was intraoperative vasopressor use and patients were grouped accordingly. The outcome variable was early total flap necrosis (flap failure within 7 days of the operation or before discharge). Univariate logistic regression was used to determine potential risk factors for early flap necrosis. Multivariate regression analyses with sequential adjustment for potential confounding factors was then performed to determine whether these factors were independently associated with flap necrosis. Meanwhile, linear regression analyses were performed with patients stratified according to age and sex to explore the relationship between risk factors and flap outcome.

**方法：** 這項前瞻性隊列研究檢查了2020年1月至2021年12月期間在北京大學口腔醫學院接受頭頸部游離組織移植手術的患者。排除標準包括術前放療或吸煙史以及美國麻醉醫師學會（ASA）體格狀態分級IV或V。預測變量為術中血管收縮劑使用，患者據此分組。結局變量為早期皮瓣全部壞死（術後7天內或出院前皮瓣失敗）。使用單變量邏輯回歸確定早期皮瓣壞死的潛在危險因素。然後進行多變量回歸分析，依次調整潛在混雜因素，以確定這些因素是否與皮瓣壞死獨立相關。同時，按年齡和性別對患者進行分層，進行線性回歸分析，探索危險因素與皮瓣結局之間的關係。

**Results:** A total of 239 participants were enrolled, with 121 in the vasopressor group and 118 in the no vasopressor group. Age, ASA classification, Charlson comorbidity index, and flap ischemia duration significantly differed between the groups. Although vasopressor use (odds ratio [OR], 1.65; 95% confidence interval [CI], 0.39-7.07; P = 0.499) was not significantly associated with flap necrosis in univariate analysis, operation duration (OR, 1.01; 95% CI, 1.01-1.01; P = 0.001) and flap ischemia duration (OR, 1.02; 95% CI, 1.01-1.03; P = 0.006) were. The smooth curve fitting results demonstrated that both operation duration and flap ischemia duration had a positive linear correlation with flap necrosis.

**結果：** 共納入239例參與者，血管收縮劑組121例，非血管收縮劑組118例。兩組在年齡、ASA分級、Charlson合併症指數和皮瓣缺血時間方面存在顯著差異。儘管在單變量分析中血管收縮劑使用（比值比[OR] 1.65；95%置信區間[CI] 0.39-7.07；P = 0.499）與皮瓣壞死無顯著相關，但手術時間（OR 1.01；95% CI 1.01-1.01；P = 0.001）和皮瓣缺血時間（OR 1.02；95% CI 1.01-1.03；P = 0.006）與之相關。平滑曲線擬合結果表明，手術時間和皮瓣缺血時間均與皮瓣壞死呈正線性相關。

**Conclusions:** Use of intraoperative vasopressors during free flap transfer surgery of the head and neck was not associated with early flap failure.

**結論：** 頭頸部游離皮瓣移植手術中術中血管收縮劑的使用與早期皮瓣失敗無關。

**Keywords:** Flap necrosis; Free flap transfer surgery; Intraoperative vasopressors; Methoxamine.

**關鍵詞：** 皮瓣壞死；游離皮瓣移植手術；術中血管收縮劑；甲氧明

---

## 13. Magnetic resonance neurography: Preoperative assessment of facial nerve invasion in malignant parotid gland tumors
**磁共振神經成像：惡性腮腺腫瘤面神經侵犯的術前評估**

**PMID: 40220868 | J Stomatol Oral Maxillofac Surg | 2025 Oct**

### Abstract / 摘要

**Backgrounds:** Facial nerve invasion (FNI) in parotid gland malignancies significantly impacts treatment outcomes and prognosis. Accurate preoperative assessment of FNI is crucial for surgical planning and tumor staging. Conventional imaging modalities often fail to visualize the facial nerve and assess FNI.

**背景：** 腮腺惡性腫瘤中的面神經侵犯（FNI）顯著影響治療結果和預後。FNI的準確術前評估對手術計劃和腫瘤分期至關重要。傳統影像學方法往往無法顯示面神經和評估FNI。

**Objects:** This study aims to evaluate the predictive efficacy of magnetic resonance neurography (MRN) in detecting FNI in parotid gland malignancies, with the goal of aiding tumor staging and treatment decision-making.

**目的：** 本研究旨在評估磁共振神經成像（MRN）檢測腮腺惡性腫瘤FNI的預測效能，以輔助腫瘤分期和治療決策。

**Methods:** 28 patients with parotid gland malignancies were included. MRN was utilized to visualize the intraparotid facial nerve and determine its relationship with the tumor. MRN results were then used to predict FNI and re-evaluate the clinical T stage. Surgical records were used for validation. Statistical analysis was performed using chi-square tests and net reclassification improvement (NRI).

**方法：** 納入28例腮腺惡性腫瘤患者。使用MRN顯示腮腺內面神經並確定其與腫瘤的關係。然後使用MRN結果預測FNI並重新評估臨床T分期。使用手術記錄進行驗證。使用卡方檢驗和淨重新分類改進（NRI）進行統計分析。

**Results:** The display rates of the main trunk and other divisions (temporofacial and cervicofacial) of the intraparotid facial nerve were 100%, 96.4%, and 96.4%, respectively. Twenty-three patients (82.1%) matched the surgical findings (P < 0.01). MRN-indicated infiltration performed better than facial paralysis in predicting FNI. Tumors of stage T4a were underestimated in 22.7% of cases (n = 5), and evaluation of clinical T stage with MRN was superior to that without MRN (NRI > 0, Z = 2.17, P = 0.03).

**結果：** 腮腺內面神經主幹和其他分支（顳面支和頸面支）的顯示率分別為100%、96.4%和96.4%。23例患者（82.1%）與手術所見相符（P < 0.01）。MRN提示的侵犯在預測FNI方面優於面癱。22.7%的病例（n = 5）中T4a期腫瘤被低估，使用MRN的臨床T分期評估優於不使用MRN（NRI > 0，Z = 2.17，P = 0.03）。

**Conclusions:** MRN can provide valuable information for predicting FNI in parotid gland malignancies, thereby improving tumor staging and aiding treatment decision-making.

**結論：** MRN可為預測腮腺惡性腫瘤FNI提供寶貴信息，從而改善腫瘤分期並輔助治療決策。

**Keywords:** Facial nerve; Magnetic resonance imaging; Neoplasm invasiveness; Neurography; Parotid neoplasms.

**關鍵詞：** 面神經；磁共振成像；腫瘤侵襲性；神經成像；腮腺腫瘤

---

## 14. Progressive functional training in patients who underwent jaw defect reconstruction using vascularized iliac flaps: A randomized controlled trial
**血管化髂骨皮瓣頜骨缺損重建患者的漸進式功能訓練：隨機對照試驗**

**PMID: 39754999 | Oral Oncol | 2025 Feb**

### Abstract / 摘要

**Objective:** This trial was aimed at investigating the effects of progressive functional training on hip mobility, lower-limb stability, quality of life, and hip complications in patients who have undergone jaw defect reconstruction using vascularized iliac flaps.

**目的：** 本試驗旨在研究漸進式功能訓練對血管化髂骨皮瓣頜骨缺損重建患者髖關節活動度、下肢穩定性、生活質量和髖關節併發症的影響。

**Methods:** Patients who underwent reconstruction surgery with vascularized iliac flaps were randomly divided into control and training groups. The control group, according to routine nursing practice, only received activity and safety guidance after the operation. The training group received progressive functional training for functional exercise. The primary outcomes were donor area function-Harris hip score and the timed "Up and Go" test. Secondary outcomes were patients' quality of life, the hip visual analog scale, and other complications. Observations and evaluations were performed before the surgery and on postoperative day 7 and at months 1, 3, 6, and 12.

**方法：** 接受血管化髂骨皮瓣重建手術的患者被隨機分為對照組和訓練組。對照組按照常規護理實踐，術後僅接受活動和安全指導。訓練組接受漸進式功能訓練進行功能鍛煉。主要結局為供區功能-Harris髖關節評分和計時"起立-行走"測試。次要結局為患者生活質量、髖關節視覺模擬量表和其他併發症。在手術前和術後第7天及第1、3、6、12個月進行觀察和評估。

**Results:** The donor area function and quality of life of the patients in the training group were significantly improved at 1, 3, 6, and 12 months after surgery, and the differences were statistically significant. The load-dependent pain in the training group was significantly reduced compared with that in the control group. The incidence rates of gait disturbance at postoperative months 3, and 6 in the training group were significantly lower than the corresponding rates in the control group (P < 0.05).

**結果：** 訓練組患者的供區功能和生活質量在術後1、3、6、12個月顯著改善，差異具有統計學意義。與對照組相比，訓練組的負重依賴性疼痛顯著減輕。訓練組術後第3、6個月的步態障礙發生率顯著低於對照組（P < 0.05）。

**Conclusion:** Progressive functional training can accelerate the restoration of hip function and stability of lower-limb movement, alleviate gait disorders, relieve pain, and improve patients' quality of life.

**結論：** 漸進式功能訓練可加速髖關節功能恢復和下肢運動穩定性，緩解步態障礙，減輕疼痛，提高患者生活質量。

**Keywords:** Donor site function; Donor site morbidity; Functional training; Jaw reconstruction; Vascularized iliac flap.

**關鍵詞：** 供區功能；供區併發症；功能訓練；頜骨重建；血管化髂骨皮瓣

---

## 翻譯練習建議

1. **專業術語注意**：
   - OSCC = 口腔鱗狀細胞癌
   - HNSCC = 頭頸部鱗狀細胞癌
   - neoadjuvant = 新輔助（治療）
   - flap = 皮瓣
   - lymph node metastasis = 淋巴結轉移
   - prognosis = 預後
   - brachytherapy = 近距離放射治療

2. **難度排序建議**：
   - 入門：#5, #8 (手術技術類，較具體)
   - 中級：#3, #6, #7, #12 (臨床研究)
   - 進階：#1, #4, #9, #10 (含分子生物學/影像組學)

3. **練習方法**：
   - 先讀 Abstract 整體理解
   - 逐段翻譯 Background/Methods/Results/Conclusion
   - 對照專業詞彙確認
